DK1904102T3 - ANTI-CCR7-receptorantistoffer til behandling af cancer - Google Patents
ANTI-CCR7-receptorantistoffer til behandling af cancerInfo
- Publication number
- DK1904102T3 DK1904102T3 DK06776128.8T DK06776128T DK1904102T3 DK 1904102 T3 DK1904102 T3 DK 1904102T3 DK 06776128 T DK06776128 T DK 06776128T DK 1904102 T3 DK1904102 T3 DK 1904102T3
- Authority
- DK
- Denmark
- Prior art keywords
- ccr7 receptor
- cancer
- treatment
- receptor antibodies
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2005/007371 WO2007003216A1 (en) | 2005-07-06 | 2005-07-06 | Anti-ccr7 receptor antibodies for the treatment of cancer |
| PCT/EP2006/006556 WO2007003426A1 (en) | 2005-07-06 | 2006-07-05 | Anti-ccr7 receptor antibodies for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1904102T3 true DK1904102T3 (da) | 2010-04-19 |
Family
ID=36021798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06776128.8T DK1904102T3 (da) | 2005-07-06 | 2006-07-05 | ANTI-CCR7-receptorantistoffer til behandling af cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8066996B2 (https=) |
| EP (1) | EP1904102B1 (https=) |
| JP (1) | JP5249025B2 (https=) |
| KR (1) | KR20080030655A (https=) |
| CN (1) | CN101257923A (https=) |
| AT (1) | ATE453407T1 (https=) |
| AU (1) | AU2006265281C1 (https=) |
| BR (1) | BRPI0612632A2 (https=) |
| CA (1) | CA2614080C (https=) |
| DE (1) | DE602006011466D1 (https=) |
| DK (1) | DK1904102T3 (https=) |
| ES (1) | ES2338919T3 (https=) |
| IL (1) | IL188594A (https=) |
| PT (1) | PT1904102E (https=) |
| RU (1) | RU2404808C2 (https=) |
| WO (2) | WO2007003216A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| EP2285403A2 (en) * | 2008-05-14 | 2011-02-23 | Msm Protein Technologies, Inc. | Human monoclonal antibodies against human chemokine receptor ccr7 |
| US9101559B2 (en) | 2009-05-08 | 2015-08-11 | New York University | Leukemic cell CNS infiltration controlled by notch-induced chemotaxis |
| WO2011040428A1 (ja) * | 2009-09-29 | 2011-04-07 | 学校法人慶應義塾 | 抗腫瘍剤およびそのスクリーニング方法 |
| AU2011309114B2 (en) * | 2010-09-28 | 2015-03-19 | Nb Health Laboratory Co., Ltd. | Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| EP2970483A2 (en) * | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
| JP6618191B2 (ja) * | 2014-03-27 | 2019-12-11 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 脳マラリアの診断および治療 |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| BR112018002877A2 (en) | 2015-08-10 | 2018-11-06 | Pepmab B.V. | humanized ccr7 receptor antibodies |
| EP3858993A1 (en) | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| WO2018073248A1 (en) | 2016-10-17 | 2018-04-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Prognosis of demyelinating diseases patients and treatment thereof |
| JOP20190187A1 (ar) * | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| US20220064311A1 (en) * | 2018-12-18 | 2022-03-03 | Catapult Therapeutics B.V. | The use of anti-CCR7 mabs for the prevention or treatment of graft-versus-host disease (GvHD) |
| US20230181756A1 (en) * | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| CN119390838B (zh) * | 2024-05-29 | 2025-06-10 | 锐胜科生物医药(上海)有限公司 | 一种靶向ccr7的纳米抗体及其制备与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| FR2818747B1 (fr) * | 2000-12-26 | 2003-05-16 | Molecular Engines Laboratoires | Procede de criblage base sur l'interaction siah-numb |
| US20020168358A1 (en) * | 2001-04-30 | 2002-11-14 | Gladue Ronald P. | Treatment of T-cell mediated diseases |
| DE10248751A1 (de) * | 2002-10-18 | 2004-05-06 | Berdel, Wolfgang E., Prof. Dr.med. | Dyslokalisationsmoleküle und deren Verwendung |
| WO2004104574A2 (en) * | 2003-05-23 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7) |
| US7807784B2 (en) * | 2003-06-11 | 2010-10-05 | The University Of Chicago | Increased T-cell tumor infiltration by mutant LIGHT |
-
2005
- 2005-07-06 WO PCT/EP2005/007371 patent/WO2007003216A1/en not_active Ceased
-
2006
- 2006-07-05 AU AU2006265281A patent/AU2006265281C1/en not_active Ceased
- 2006-07-05 DE DE602006011466T patent/DE602006011466D1/de active Active
- 2006-07-05 EP EP06776128A patent/EP1904102B1/en active Active
- 2006-07-05 ES ES06776128T patent/ES2338919T3/es active Active
- 2006-07-05 CA CA2614080A patent/CA2614080C/en active Active
- 2006-07-05 BR BRPI0612632-4A patent/BRPI0612632A2/pt not_active Application Discontinuation
- 2006-07-05 US US11/994,833 patent/US8066996B2/en active Active
- 2006-07-05 DK DK06776128.8T patent/DK1904102T3/da active
- 2006-07-05 AT AT06776128T patent/ATE453407T1/de active
- 2006-07-05 WO PCT/EP2006/006556 patent/WO2007003426A1/en not_active Ceased
- 2006-07-05 PT PT06776128T patent/PT1904102E/pt unknown
- 2006-07-05 RU RU2008104420/10A patent/RU2404808C2/ru active
- 2006-07-05 JP JP2008519857A patent/JP5249025B2/ja not_active Expired - Fee Related
- 2006-07-05 KR KR1020087003130A patent/KR20080030655A/ko not_active Ceased
- 2006-07-05 CN CNA2006800323035A patent/CN101257923A/zh active Pending
-
2008
- 2008-01-03 IL IL188594A patent/IL188594A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006011466D1 (de) | 2010-02-11 |
| RU2008104420A (ru) | 2009-08-20 |
| AU2006265281C1 (en) | 2012-11-15 |
| AU2006265281B2 (en) | 2012-03-01 |
| BRPI0612632A2 (pt) | 2012-01-03 |
| US20090123483A1 (en) | 2009-05-14 |
| ES2338919T3 (es) | 2010-05-13 |
| ATE453407T1 (de) | 2010-01-15 |
| CN101257923A (zh) | 2008-09-03 |
| JP2008545000A (ja) | 2008-12-11 |
| JP5249025B2 (ja) | 2013-07-31 |
| EP1904102B1 (en) | 2009-12-30 |
| IL188594A (en) | 2012-02-29 |
| CA2614080A1 (en) | 2007-01-11 |
| WO2007003426A1 (en) | 2007-01-11 |
| AU2006265281A1 (en) | 2007-01-11 |
| US8066996B2 (en) | 2011-11-29 |
| IL188594A0 (en) | 2008-04-13 |
| CA2614080C (en) | 2014-08-26 |
| KR20080030655A (ko) | 2008-04-04 |
| WO2007003216A1 (en) | 2007-01-11 |
| EP1904102A1 (en) | 2008-04-02 |
| PT1904102E (pt) | 2010-03-29 |
| RU2404808C2 (ru) | 2010-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL188594A0 (en) | Anti-ccr7 receptor antibodies for the treatment of cancer | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| JOP20210071A1 (ar) | أجسام مضادة مثبّتة trem2 | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| EA201070636A1 (ru) | Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения | |
| BRPI0919473A2 (pt) | Agentes de ligação frizzled e usos dos mesmos | |
| DOP2012000052A (es) | Proteínas terapéuticas de unión a dll4 | |
| EA201170716A1 (ru) | Антитела к с-мет | |
| EA200971077A1 (ru) | Гетероциклические модуляторы киназы | |
| MX373790B (es) | Anticuerpos humanos a ligando de muerte programada 1 (pd-l1). | |
| ECSP14001260A (es) | Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas | |
| CY1112739T1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης | |
| EA201401107A1 (ru) | Специфические антагонисты рецептора fgf-r4 | |
| EA201100923A1 (ru) | Антитела человека против тканевого фактора | |
| MX385545B (es) | Anticuerpos humanos para pd-1. | |
| MX2010006767A (es) | Anticuerpos de virus de hepatitis c. | |
| EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
| BR112016025437A2 (pt) | combinação de lenalidomida e construto de polipeptídeo, e usos destes | |
| CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
| UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
| EA201070730A1 (ru) | Гуманизированные антитела, специфичные к фактору фон виллебранда | |
| GT200900002A (es) | Anticuerpo antagonista para el tratamiento del cancer | |
| EA201591762A1 (ru) | Человеческие антитела к grem1 | |
| ATE528319T1 (de) | Krebsbehandlung mit anti-il-1-antikörpern | |
| EA201270662A1 (ru) | Связывающие элементы для человеческого цитамегаловируса |